

Asthma and Pregnancy

Case related questions.

Scenario:

Ms. M is a 23-year-old woman with a history of asthma. She is 26 weeks pregnant with her second child and is referred to you by obstetrics for management of her asthma. She complains of increasing fatigue and dyspnea on exertion with 2 flights of stairs. She has never been hospitalized or intubated for asthma but was admitted for a brief stay for pneumonia 1 year ago and was found to have influenza B at that time. She uses albuterol as needed, which she currently requires twice daily. She smokes about 7 cigarettes a day and is trying to cut down. She is taking prenatal vitamins. She has not seen a pulmonologist and has Medicaid insurance pending secondary to her pregnancy. On review of systems, she also complains of rhinitis, heartburn, lower extremity swelling and weight gain. In the office she is comfortable appearing. Her resting oxygen saturation (SpO₂) on room air is 97%. Her other vital signs are within normal limits and the pulmonary exam is unremarkable. She has a gravid abdomen and trace lower extremity edema.

Question 1: What are the effects of pregnancy on the natural history of asthma, and how does asthma impact pregnancy? Are pulmonary function tests (PFTs) and peak flows reliable?


Question 2: What are the safety data or potential adverse effects of commonly used maintenance therapy in asthma (i.e., short-acting beta-agonists (SABA), long-acting beta-agonists (LABA), and inhaled corticosteroids (ICS))? What about systemic corticosteroids? What about biologics? Are patients more likely to be adherent to medication therapy during pregnancy?

Question 3: How do you counsel your patient on SABA/LABA and inhaled corticosteroids (ICS) risks while breastfeeding?

Question 4: What about smoking cessation therapy?

Question 5: What are the management principles during an acute asthma exacerbation in pregnancy?

Question 6: What medications are effective for allergic rhinitis?



Asthma and Pregnancy

Author Sarah Lyon, MD, MSCE

Editor Amik Sodhi, MBBS, MPH

*Literature review current through June 2025
Last updated June 2025*

Citation

Turetz M, Miller W, et al., Asthma and Pregnancy. In: Lyon S. Association of Pulmonary and Critical Care Program Directors Ambulatory Care Teaching Scripts. 2025. <https://apccmpdscholars.org/tool/ambulatory-care-curriculum/>.

Section Editors

2025 Meredith Turetz, MD
William Miller, MD, MS
2023 Hetal Patel, MD
Laura Hinkle, MD, MEd
2021 May M. Lee, MD
Wei Jung Hisa, MD
David J. De La Zerda, MD

Educational Objectives


1. Examine the relationship between asthma and pregnancy
2. Discuss the pharmacologic management of asthma during pregnancy and lactation
3. Review medication safety during pregnancy
4. Review management principles of asthma exacerbation during pregnancy
5. Discuss the management of smoking cessation and allergic rhinitis in the pregnant patient

Scenario:

Ms. M is a 23-year-old woman with a history of asthma. She is 26 weeks pregnant with her second child and is referred to you by obstetrics for management of her asthma. She complains of increasing fatigue and dyspnea on exertion with 2 flights of stairs. She has never been hospitalized or intubated for asthma but was admitted for a brief stay for pneumonia 1 year ago and was found to have influenza B at that time. She uses albuterol as needed, which she currently requires twice daily. She smokes about 7 cigarettes a day and is trying to cut down. She is taking prenatal vitamins. She has not seen a pulmonologist and has Medicaid insurance pending secondary to her pregnancy. On review of systems, she also complains of rhinitis, heartburn, lower extremity swelling and weight gain. In the office she is comfortable appearing. Her resting oxygen saturation (SpO₂) on room air is 97%. Her other vital signs are within normal limits and the pulmonary exam is unremarkable. She has a gravid abdomen and trace lower extremity edema.

Question 1: What are the effects of pregnancy on the natural history of asthma, and how does asthma impact pregnancy? Are pulmonary function tests (PFTs) and peak flows reliable?

Asthma is the most common chronic disease in pregnancy, impacting 8-9% of all pregnancies in the United States.¹



The traditional teaching is that 1/3 of asthma patients will worsen during pregnancy, 1/3 will stay the same, and 1/3 will improve. However, in a recent study of >300 pregnant women with asthma, approximately 60% had asthma that stayed the same, 40% had asthma that worsened, and no women were noted to have asthma that improved.² A review and metaanalysis of studies from 1955-2003 suggested that asthma exacerbations in pregnancy cluster around the end of the second trimester. Risk factors include severe asthma, viral infection, and maternal or health care provider concerns surrounding asthma medications leading to reduction or cessation of therapy.^{3,4}

Table. Physiologic Changes in Pregnancy⁵

Measurement	Change	Clinical Correlate
Forced vital capacity	None	
Forced expiratory volume in 1 second	None	
Minute ventilation	Increased by ~50%	Subjective shortness of breath ("dyspnea of pregnancy"), mild respiratory alkalosis
Tidal volume	Increased by ~40%	
Diaphragm elevation	~4cm near term	Contributes to SOB at term
Total lung capacity, expiratory reserve volume, residual volume, functional residual capacity	All decreased	
Upper airway vascular and mucus congestion	Increase	Pregnancy rhinitis (non-allergic), snoring

Adapted from Couillard et al.⁵

Arterial blood gases

- Minute ventilation increases during pregnancy due to increased levels of progesterone and exceeds metabolic demands. This causes:
 - Primary respiratory alkalosis
 - Compensatory renal loss of bicarbonate (decreased to 18-21)
 - Decreased partial pressure of arterial carbon dioxide (PaCO_2 , typical range 28-30 mmHg) and an increased partial pressure of arterial oxygen (PaO_2 , typical range 100-106 mm Hg)
- Normal pH during pregnancy is 7.4 to 7.45, with slightly elevated pO_2 of 100-105 mmHg
- A $\text{PaCO}_2 > 35 \text{ mmHg}$ or a $\text{PaO}_2 < 70$ represents more severe compromise

Effects of Uncontrolled Asthma on Pregnancy

While a maternal diagnosis of asthma minimally increases the risk of maternal-fetal complications, this risk rises dramatically if maternal asthma is not controlled, with significantly higher risks of^{5,6}:

- Congenital malformations
- Preterm births
- Low birth weight
- Pregnancy-induced hypertension/pre-eclampsia
- Infant pneumonia/asthma

Question 2: What are the safety data or potential adverse effects of commonly used maintenance therapy in asthma (i.e., short-acting beta-agonists (SABA), long-acting beta-agonists (LABA), and inhaled corticosteroids (ICS))? What about systemic corticosteroids? What about biologics? Are patients more likely to be adherent to medication therapy during pregnancy?

Approximately half of the pregnant women who were on asthma therapy before pregnancy are likely to **stop or decrease** their use of their asthma medications on their own or under the advice of a healthcare provider.^{6,7}

General Take Home: Maintaining asthma control has been shown to benefit both mom and baby. Treatment of asthma is safer than uncontrolled asthma.³ Stepping down asthma therapy is not a priority during pregnancy due to the risks of uncontrolled asthma to mother and baby.³

Maintenance Medications^{1,6} – SABA/LABA/ICS have minimal adverse effects on pregnancy and should be continued.⁶ Emphasis on education and non-pharmacologic control should also be maintained.

Albuterol – Most large studies have shown no increased risk of major birth defects. A few have shown a moderately increased risk of cleft lip/palate, gastroschisis, esophageal atresia, cardiac defects, or omphalocele.

LABA – Always used in combination with ICS due to the risk of sudden death in asthmatics taking a LABA as monotherapy. Preferred choices include salmeterol and formoterol. A study of 841 pregnant asthmatics taking a LABA with an ICS showed no increased risk of birth defects compared with those taking only an ICS.

ICS – A meta-analysis published in 2013 found no increase in stillbirth, congenital malformations, or rate of c-section in those with maternal ICS use vs. those without.⁸ Because of the initial available human data from a Swedish cohort study, budesonide is considered the preferred ICS and there is also some safety data for fluticasone. If a pregnant woman is well controlled on other ICS, these should be continued rather than change the ICS preparation.

Oral steroids – A recent US National Birth Defects Prevention study showed no increased risk for cleft lip/palate with the use of oral steroids in the first trimester. No other major birth defects were noted.

LAMA – Some animal studies have shown teratogenicity. There is currently no human data surrounding its safety in pregnancy.^{7,9}

Leukotriene modifiers – Large studies have not demonstrated an increased risk of major birth defects in exposed pregnancies.⁶

Biologics – All currently available biologics will cross the placenta and there are no major guidelines regarding use of biologics during pregnancy, though recent literature suggests benefits may outweigh risks, and there are ongoing observation studies regarding pregnancy and biologics.⁵ Omalizumab is typically the preferred biologic in pregnancy as it has the most data in pregnancy, with no concerns for teratogenicity. Animal studies of mepolizumab and bevacizumab have not shown any adverse outcomes, and limited data

surrounding mepolizumab in human pregnancies have not demonstrated adverse maternal or fetal outcomes.¹⁰

Initiation of biologics while pregnant is not recommended due to the small risk of anaphylaxis with these medications.^{5,11}

Question 3: How do you counsel your patient on SABA/LABA and ICS risks while breastfeeding?

In general, inhaled drugs do not result in significant systemic drug levels. Infant exposure to these medications through breastfeeding is markedly less than in utero. The amount ingested would generally be <3% of a weight-based therapeutic dose. Systemic steroids are not significantly excreted in breast milk, but to further reduce infant exposure avoiding feeds for a few hours after each dose could be considered.¹²

Question 4: What about smoking cessation therapy?

35-75% of women who smoke quit while pregnant.^{13,14} Most who quit do so independently without intervention during the first trimester. Quitting early is best, but quitting any time is good.^{13,14}

Evidence from 5 cohort studies shows no harm to fetuses resulting from smoking cessation interventions compared to mothers who smoked. This includes the following:

Behavioral Therapies: A review of 97 study groups showed a statistically significant association with smoking cessation in later pregnancy with evidence that postpartum smoking abstinence continued for up to 18 months.

Nicotine replacement therapy has no clear evidence of fetal harmfulness, but data are unclear. The NRT inhaler may be associated with higher mean birth weight, while the patch is not.¹⁵

Bupropion and Varenicline – Cochrane Database meta-analysis in 2020 showed no evidence that bupropion was effective in smoking cessation in pregnancy, and minimal studies exist looking at safety data. Fewer placebo-controlled studies exist evaluating varenicline.¹⁶

Question 5: What are the management principles during an acute asthma exacerbation in pregnancy?

Up to 45% of pregnant women are reported to have an asthma exacerbation and the mean gestational age for acute asthma exacerbation is in the late second trimester.^{1,3}

Surprisingly, exacerbations during labor and delivery are not common.³ Due to the increased minute ventilation during pregnancy, normal blood gas has a PaCO₂ of 28-30. Therefore, PaCO₂ >35 mmHg or PaO₂ <70 mmHg during an acute asthma exacerbation indicates more severe impending respiratory failure.¹⁴ The following interventions can be used:

1. Oxygen supplementation to keep O₂ saturation > 95%.
2. Beta-agonist bronchodilators via metered dose inhaler or nebulizers
3. Inhaled ipratropium
4. Systemic glucocorticoids – Use is similar to nonpregnant patients, and benefits with risks should be balanced
5. Intravenous magnesium is well studied in pregnancy at 2gm over 20 minutes
6. Subcutaneous terbutaline at 0.25mg every 20 minutes for 3 doses

Recommendation for treatment of acute asthma exacerbation in pregnant patients remains essentially the same as in nonpregnant adults, with the caveat that special attention should be paid to avoid O₂ saturations less than 95% to prevent fetal hypoxemia.

Question 6: What medications are effective for allergic rhinitis?

Glucocorticoid nasal sprays are highly effective for allergic rhinitis. Safety data is extrapolated from ICS data, and a large 2016 study confirms this.¹⁶ First-generation oral histamines have significant safety data, especially chlorpheniramine. Among second-generation oral histamines, loratadine and cetirizine have reassuring human data.¹⁷

References

1. Namazy JA, Schatz M. Chronic Management of Asthma During Pregnancy. *Immunol Allergy Clin North Am*. Feb 2023;43(1):65-85. doi:10.1016/j.iac.2022.09.001
2. Stevens DR, Perkins N, Chen Z, Kumar R, Grobman W, Subramaniam A, Biggio J, Grantz KL, Sherman S, Rohn M, Mendola P. Determining the Clinical Course of Asthma in Pregnancy. *J Allergy Clin Immunol Pract*. 2022 Mar;10(3):793-802.
3. Murphy VE, Clifton VL, Gibson PG. Asthma exacerbations during pregnancy: incidence and association with adverse pregnancy outcomes. *Thorax*. 2006 Feb;61(2):169-76. doi: 10.1136/thx.2005.049718. PMID: 16443708; PMCID: PMC2104591.
4. Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention. Accessed 1/8/2025, www.ginasthma.org
5. Couillard S, Connolly C, Borg C, Pavord I. Asthma in pregnancy: An update. *Obstet Med*. Sep 2021;14(3):135-144. doi:10.1177/1753495X20965072
6. Colas K, Namazy J. Asthma in pregnancy: a review of recent literature. *Curr Opin Pulm Med*. 2024 May 1;30(3):313-324.
7. Robijn AL, Murphy VE, Gibson PG. Recent developments in asthma in pregnancy. *Curr Opin Pulm Med*. Jan 2019;25(1):11-17. doi:10.1097/MCP.0000000000000538
8. Murphy VE, Wang G, Namazy JA, et al. The risk of congenital malformations, perinatal mortality and neonatal hospitalisation among pregnant women with asthma: a systematic review and meta-analysis. *BJOG* 2013; 120: 81-822
9. Namazy JA, Schatz M. Management of Asthma during Pregnancy: Optimizing Outcomes and Minimizing Risk. *Semin Respir Crit Care Med*. Feb 2018;39(1):29-35. doi:10.1055/s-0037-1606216
10. L Ramos C, Namazy J. Monoclonal Antibodies (Biologics) for Allergic Rhinitis, Asthma, and Atopic Dermatitis During Pregnancy and Lactation. *Immunol Allergy Clin North Am*. 2023 Feb;43(1):187-197.
11. Namazy JA, Blais L, Andrews EB, et al. Pregnancy outcomes in the omalizumab pregnancy registry and a disease-matched comparator cohort. *Journal of Allergy and Clinical Immunology*. 2020;145(2):528-536. e1.
12. Lim A, Hussainy, SF, Abramson, MJ. Asthma Drugs in Pregnancy and Lactation. *Australian Prescriber*. 2013;36(5)
13. Alves E, Azevedo A, Correia S, Barros H. Long-term maintenance of smoking cessation in pregnancy: an analysis of the birth cohort generation XXI. *nicotine & tobacco research*. 2013;15(9):1598-1607.
14. Tong VT, Dietz PM, Farr SL, D'angelo DV, England LJ. Estimates of smoking before and during pregnancy, and smoking cessation during pregnancy: comparing two population-based data sources. *Public health reports*. 2013;128(3):179-188.
15. Patnode CD, Henderson JT, Coppola EL, Melnikow J, Durbin S, Thomas RG. Interventions for tobacco cessation in adults, including pregnant persons: updated evidence report and systematic review for the US Preventive Services Task Force. *Jama*. 2021;325(3):280-298.
16. Claire R, Chamberlain C, Davey MA, et al. Pharmacological interventions for promoting smoking cessation during pregnancy. *Cochrane database of systematic reviews*. 2020;(3)
17. Bérard A, Sheehy O, Kurzinger M-L, Juhaeri J. Intranasal triamcinolone use during pregnancy and the risk of adverse pregnancy outcomes. *Journal of Allergy and Clinical Immunology*. 2016;138(1):97-104. e7.
18. Källén B. Use of antihistamine drugs in early pregnancy and delivery outcome. *The Journal of Maternal-Fetal & Neonatal Medicine*. 2002;11(3):146-152.

Asthma and Pregnancy

Post-Test Case Related Questions

1. Many physiologic changes occur in a woman's body during pregnancy. Which of the following is true regarding typical physiologic changes seen on PFTs:
 - a. RV and FRC are typically decreased
 - b. FEV1 typically decreases in the late 2nd and throughout the 3rd trimester
 - c. FEV1/FVC ratio decreases
 - d. VC increases
2. A 28-year-old female with a history of asthma is 22 weeks pregnant. She has a history of asthma and was previously well-maintained on inhaled steroids but has not been treated with regular inhaled therapies in the last 2 years. She reports a recent increase in symptoms, with symptoms on average 3 days a week. She denies any nighttime symptoms. She requires the use of her albuterol inhaler about 3 days a week. Which of the following would you recommend in terms of therapy?
 - a. Initiate low dose budesonide
 - b. Defer initiation of inhaled steroids, given the risk to the fetus
 - c. Continue albuterol as needed alone
 - d. Start low dose fluticasone-salmeterol
 - e. Start oral prednisone and monitor for symptom improvement
3. A 31-year-old female with a history of asthma is referred to you by OB/GYN to evaluate and treat her poorly controlled asthma. She is 2 weeks postpartum, and her delivery was uncomplicated. Her baby is home and doing well. She notes that she has had significant wheezing and chest tightness since starting with some upper respiratory viral symptoms a week prior. In your best assessment, she has an acute asthma exacerbation, but you believe she can be managed safely as an outpatient. You do not think she warrants antibiotics but requires additional medical therapy beyond her current albuterol PRN. Which of the following is **FALSE** regarding outpatient management of an asthma exacerbation in this patient?
 - a. Inhaled steroids are likely compatible with this setting
 - b. Oral/systemic prednisone concentrations are high in breast milk and should be avoided.
 - c. She can safely continue her albuterol inhaler
 - d. Influenza vaccines are safe to administer to the breastfeeding mother

Asthma and Pregnancy

Post-Test Case Related Questions with Answer Key

- Many physiologic changes occur in a woman's body during pregnancy. Which of the following is true regarding typical physiologic changes seen on PFTs:
 - RV and FRC are typically decreased
 - FEV1 typically decreases in the late 2nd and throughout the 3rd trimester
 - FEV1/FVC ratio decreases
 - VC increases
- A 28-year-old female with a history of asthma is 22 weeks pregnant. She has a history of asthma and was previously well-maintained on inhaled steroids but has not been treated with regular inhaled therapies in the last 2 years. She reports a recent increase in symptoms, with symptoms on average 3 days a week. She denies any nighttime symptoms. She requires the use of her albuterol inhaler about 3 days a week. Which of the following would you recommend in terms of therapy?
 - Initiate low dose budesonide
 - Defer initiation of inhaled steroids, given the risk to the fetus
 - Continue albuterol as needed alone
 - Start low dose fluticasone-salmeterol
 - Start oral prednisone and monitor for symptom improvement
- A 31-year-old female with a history of asthma is referred to you by OB/GYN to evaluate and treat her poorly controlled asthma. She is 2 weeks postpartum, and her delivery was uncomplicated. Her baby is home and doing well. She notes that she has had significant wheezing and chest tightness since starting with some upper respiratory viral symptoms a week prior. In your best assessment, she has an acute asthma exacerbation, but you believe she can be managed safely as an outpatient. You do not think she warrants antibiotics but requires additional medical therapy beyond her current albuterol PRN. Which of the following is **FALSE** regarding outpatient management of an asthma exacerbation in this patient?
 - Inhaled steroids are likely compatible with this setting
 - Oral/systemic prednisone concentrations are high in breast milk and should be avoided.
 - She can safely continue her albuterol inhaler
 - Influenza vaccines are safe to administer to the breastfeeding mother